News
Merck KGaA's BTK drug reduces lesions in relapsing MS patien...
Germany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) class drug evobrutinib reduced occurrence of central nervous system lesion
